After 12 weeks of nebulized NAC, patients’ mean phlegm scores, as measured by the COPD assessment test, significantly decreased from 3.47 at baseline to 2.62. N-acetylcysteine (NAC) nebulizer ...
The Spanish COPD guidelines recommend treatment of the mixed COPD–asthma phenotype with ICS and a long-acting bronchodilator (LABD) as a first option to improve lung function, respiratory ...
According to Research by SNS Insider, Nebulizer Market Growth is Driven by Rising Prevalence of Chronic Respiratory Diseases and Technological Advancements.Austin, Oct. 18, 2024 (GLOBE NEWSWIRE) -- ...
Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...
Inhalers used to treat symptoms of respiratory disease can be potent sources of greenhouse gases. Drugmakers are planning to ...
Two posters presented at the CHEST 2024 annual meeting showed that mepolizumab significantly reduces exacerbations in ...
Steroid tablets are associated with significant adverse side effects. Short-term use risks sleep disturbance, reflux, ...
Patients with asthma and COPD routinely switch from pressurized metered-dose inhalers to dry powder inhalers and vice versa.
The global airway disease treatment market is projected to experience significant growth over the next decade, with revenue ...
People who suffer from asthma in Ireland have significant levels of steroid use, including children, a new survey reveals ...
N-acetylcysteine (NAC) nebulizer therapy is effective and safe in the short-term (12 weeks) for reducing phlegm in COPD.
The Asthma Society of Ireland has warned that over-use of steroid medication may cause more harm than good. A study has shown ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback